Cogent Biosciences

COGT

Market cap $1.77B

Overview Fund Activity

12.66 USD

-0.15

1.17%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

12.66

0.00

0%

1 day

-1.17%

5 days

-3.21%

1 month

9.61%

3 months

75.35%

6 months

66.8%

Year to date

62.31%

1 year

23.27%

5 years

17.22%

10 years

-71.51%

About: Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Employees: 205

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 9 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

214% more call options, than puts

Call options by funds: $20.5M | Put options by funds: $6.52M

111% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 37

22% more capital invested

Capital invested by funds: $800M [Q1] → $973M (+$174M) [Q2]

13% more funds holding in top 10

Funds holding in top 10: 8 [Q1] → 9 (+1) [Q2]

1.78% more ownership

Funds ownership: 117.25% [Q1] → 119.04% (+1.78%) [Q2]

3% less funds holding

Funds holding: 185 [Q1] → 179 (-6) [Q2]

15% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 34

See Fund Rankings

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$9

-29% downside

Avg. target

$22

71% upside

High target

$30

137% upside

9 analyst ratings

8 positive

89%

1 neutral

11%

0 negative

0%

Raymond James Chris Raymond	$30	Strong Buy Initiated	3 Sep 2025
Guggenheim Charles Zhou	$20	Buy Maintained	25 Aug 2025
JP Morgan Anupam Rama	$30	Overweight Maintained	7 Aug 2025
HC Wainwright & Co. Robert Burns	$21	Buy Maintained	6 Aug 2025
Citigroup David Lebowitz	$22	Buy Maintained	18 Jul 2025
Guggenheim Michael Schmidt	$17	Buy Reiterated	8 Jul 2025
Baird Joel Beatty	$9	Neutral Maintained	8 Jul 2025
Leerink Partners Andrew Berens	$18	Outperform Maintained	7 Jul 2025
Jefferies Kelly Shi	$28	Buy Maintained	7 Jul 2025

See Analyst Rankings

Financial journalist opinion

Cogent Biosciences, Inc. (COGT) Presents At Citi's Biopharma Back To School Conference Transcript

Cogent Biosciences, Inc. (NASDAQ:COGT ) Citi's Biopharma Back to School Conference September 3, 2025 9:00 AM EDT Company Participants Andrew Robbins - President, CEO & Director Conference Call Participants David Lebowitz - Citigroup Inc., Research Division Presentation David Lebowitz Research Analyst Good morning. Thank you for coming to the 2025 Citi Biopharma Conference in Boston.

Cogent Biosciences, Inc. (COGT) Presents At Citi's Biopharma Back To School Conference Transcript

Cogent Biosciences Announces Participation in the Citi Biopharma Conference

WALTHAM, Mass. and BOULDER, Colo.

Cogent Biosciences Announces Participation in the Citi Biopharma Conference

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Reported positive top-line results from SUMMIT evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis, achieving statistical significance across all primary and key secondary endpoints On track to share pivotal trial results from PEAK in GIST and APEX in AdvSM in 2H 2025 $453 million in pro-forma cash sufficient to fund operations through anticipated launch and into 2027; includes proceeds from upsized $230 million public offering in July 2025 WALTHAM, Mass. and BOULDER, Colo.

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results

24/7 Wall Street

2 Biotech and 2 Tech Stocks Insiders Are Scooping Up Now

Insider buying has been slow this month, as buy windows close ahead of the new earnings-reporting season.

2 Biotech and 2 Tech Stocks Insiders Are Scooping Up Now

Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

WALTHAM, Mass. and BOULDER, Colo., July 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its previously announced upsized underwritten public offering of 25,555,556 shares of its common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The public offering price was $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were sold by Cogent.

Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results

I have upgraded Cogent Biosciences, Inc. to Strong Buy after positive SUMMIT trial data for bezuclastinib in non-advanced systemic mastocytosis patients. COGT plans to submit an NDA for bezuclastinib in NonAdvSM by end of 2025, with additional pivotal data readouts expected in AdvSM and GIST in 2nd half 2025. Cogent is well-funded, raising $200M recently and maintaining a cash runway into late 2026, supporting ongoing and upcoming clinical milestones.

Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Cogent. The offering is expected to close on or about July 10, 2025, subject to the satisfaction of customary closing conditions.

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $150 million of its shares of common stock. In addition, Cogent intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its shares of common stock on the same terms and conditions. All of the securities in the offering are being offered by Cogent. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock

Zacks Investment Research

COGT Stock Soars on Phase III Systemic Mastocytosis Study Success

Cogent Biosciences stock jumps 23.4% after bezuclastinib hits primary and all key secondary endpoints in a phase III systemic mastocytosis study.

COGT Stock Soars on Phase III Systemic Mastocytosis Study Success

Why Is Cogent Biosciences Stock Trading Higher On Monday?

Cogent Biosciences, Inc.‘s COGT bezuclastinib showed meaningful clinical benefit for patients with non-advanced systemic mastocytosis, a rare and debilitating immune disorder.

Why Is Cogent Biosciences Stock Trading Higher On Monday?

See News Rankings

Charts implemented using Lightweight Charts™